Company: MDCXW
Filing Date: 2025-06-30
Form Type: DEF 14A
Source: 0001062993-25-012273
Chunk: 51

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-30
Form: DEF 14A
Chunk 51
---
uneration policies, including the total remuneration (including benefits) and the main components thereof for the directors and senior executives, and to compare such remuneration policies with the remuneration practices of peers in the same industry;

reviewing and recommending to the Board for its approval the disclosure required in any management information circular in respect of meetings of our Shareholders relating to executive compensation and finalizing the report on executive compensation in any management information circular;

determining those directors, officers, employees and consultants of the Company who will participate in long term incentive plans, the number and type of shares of the Company allocated to each participant under such plan and the time or times when ownership of such shares will vest for each participant;

administering all matters relating to any long term incentive plan and any employee bonus plan to which the Committee has been delegated authority pursuant to the terms of such plans or any resolutions passed by the Board;

annually recommending to the Board the CEO's and senior executives' entitlement to be paid a bonus under any employee bonus plan;

reviewing on an annual basis, its mandate and recommending any proposed changes to the Board;

reporting regularly to the Board in relation to any matters arising from its review of compensation practices; and

evaluating the function of the Compensation Committee on an annual basis.

A copy of the Compensation Committee Charter is available on our corporate website at www.medicuspharma.com/corporate-govenance/.

Nominating Committee

The primary function of the Nominating Committee, in accordance with its charter, is to assist the Board in fulfilling its responsibility to oversee our nominating procedures.

The Nominating Committee is required to review and assess the adequacy of its charter periodically as conditions dictate, but at least annually, to ensure compliance with any rules or regulations and recommend any modifications to its charter if and when appropriate to the Board for its approval.

Nominating Committee Composition

As of the date of this report, the Nominating Committee is comprised of three members as set forth in the following table:

| Name                 |     | Whether Independent(1) |
| William L. Ashton    |     | Independent            |
| Barry Fishman        |     | Independent            |
| Dr. Larry Kaiser (2) |     | Independent            |

<div align='center'>41</div>

Notes:

(1)A member of the Nominating Committee is independent if he or she has no direct or indirect 'material relationship' with the Company. A material relationship is a relationship which could,